HomeCompareEICB vs ABBV

EICB vs ABBV: Dividend Comparison 2026

EICB yields 7.76% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EICB wins by $1.0K in total portfolio value
10 years
EICB
EICB
● Live price
7.76%
Share price
$24.97
Annual div
$1.94
5Y div CAGR
23.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$103.3K
Annual income
$24,920.49
Full EICB calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — EICB vs ABBV

📍 EICB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEICBABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EICB + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EICB pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EICB
Annual income on $10K today (after 15% tax)
$659.55/yr
After 10yr DRIP, annual income (after tax)
$21,182.42/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, EICB beats the other by $126.41/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EICB + ABBV for your $10,000?

EICB: 50%ABBV: 50%
100% ABBV50/50100% EICB
Portfolio after 10yr
$102.8K
Annual income
$24,846.12/yr
Blended yield
24.16%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

EICB
No analyst data
Altman Z
1.6
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EICB buys
0
ABBV buys
0
No recent congressional trades found for EICB or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEICBABBV
Forward yield7.76%3.06%
Annual dividend / share$1.94$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR23.2%40.6%
Portfolio after 10y$103.3K$102.3K
Annual income after 10y$24,920.49$24,771.77
Total dividends collected$72.7K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EICB vs ABBV ($10,000, DRIP)

YearEICB PortfolioEICB Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,656$955.96$11,550$430.00+$106.00EICB
2$13,755$1,282.96$13,472$627.96+$283.00EICB
3$16,461$1,743.20$15,906$926.08+$555.00EICB
4$20,015$2,401.99$19,071$1,382.55+$944.00EICB
5$24,779$3,362.83$23,302$2,095.81+$1.5KEICB
6$31,307$4,793.55$29,150$3,237.93+$2.2KEICB
7$40,472$6,973.37$37,536$5,121.41+$2.9KEICB
8$53,685$10,379.61$50,079$8,338.38+$3.6KEICB
9$73,295$15,852.71$69,753$14,065.80+$3.5KEICB
10$103,346$24,920.49$102,337$24,771.77+$1.0KEICB

EICB vs ABBV: Complete Analysis 2026

EICBStock

Eagle Point Income Company manages capital on behalf of institutional, high-net-worth, and retail investors through private funds, separately managed accounts, and publicly-listed closed-end vehicles. They provide CLO securities and related investments. The investment objective is to generate high current income, with a secondary objective to generate capital appreciation.

Full EICB Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this EICB vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EICB vs SCHDEICB vs JEPIEICB vs OEICB vs KOEICB vs MAINEICB vs JNJEICB vs MRKEICB vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.